Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Vertex Pharmaceuticals (VRTX)

NASDAQ: VRTX · Biotechnology · Boston, MA

Our rating: Positive

Positive reaffirmed at $549.04, moderate conviction, November 4, 2026.

Breaks if: The Positive call is undermined if revenue growth in two consecutive quarterly filings over the next twelve months decelerates below 5% — at that rate the 35.8x earnings multiple loses its anchor and the view tips toward Neutral or Cautious. The call would need to escalate to Conviction if free cash flow closes to within $300M of net income across two straight quarterly filings while a second material revenue stream appears at reportable scale in the company's disclosures.

Key figures

Market value$130.6B
Revenue, last 12 months$13.0B
Net income, last 12 months$4.0B
Free cash flow, last 12 months$3.2B
Price to earnings32.8×
Free cash flow yield2.5%
Dividend yield0.0%
Operating margin33.2%
Return on equity20.8%
Beta to the S&P 5000.46
Volatility, annualized30.8%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$3.4B11.8%$2.56$546M
June 30, 2026$3.3B12.5%$4.31$1.0B
March 31, 2026$3.0B7.8%$4.02$1.3B
December 31, 2025$3.2B9.5%$4.64$349M
September 30, 2025$3.1B11.0%$4.20$1.1B
June 30, 2025$3.0B12.1%$3.99$927M
March 31, 2025$2.8B3.0%$2.49$778M
December 31, 2024$2.9B15.7%$3.53$492M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 15 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.